Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Cobitolimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InDex Pharmaceuticals discontinues cobitolimod phase III program
    InDex Pharmaceuticals discontinues cobitolimod phase III program

    22 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/index-pharmaceuticals-discontinues-cobitolimod-phase-iii-program-301995261.html

    PR NEWSWIRE
    22 Nov 2023
    Share Share
    InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE
    InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE

    11 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/index-pharmaceuticals-announces-that-all-patients-needed-for-the-cobitolimod-dose-selection-milestone-have-completed-induction-study-1-of-the-phase-iii-program-conclude-301953209.html

    PR NEWSWIRE
    11 Oct 2023
    Share Share
    Positive results from PK study with cobitolimod' selected as one of the best abstracts for presentation
    Positive results from PK study with cobitolimod' selected as one of the best abstracts for presentation

    22 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/positive-results-from-pk-study-with-cobitolimod-selected-as-one-of-the-best-abstracts-for-poster-presentation-at-uegw-index-pharmaceuticals-301906507.html

    PR NEWSWIRE
    22 Aug 2023
    Share Share
    InDex Pharma has been granted a new patent in Europe for cobitolimod
    InDex Pharma has been granted a new patent in Europe for cobitolimod

    02 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/index-pharmaceuticals-has-been-granted-a-new-patent-in-europe-for-the-commercial-formulation-of-cobitolimod-301891270.html

    PR NEWSWIRE
    02 Aug 2023
    Share Share
    InDex announces positive results from PK study with cobitolimod
    InDex announces positive results from PK study with cobitolimod

    15 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/index-pharmaceuticals-announces-positive-results-from-a-pharmacokinetic-pk-study-with-cobitolimod-301772697.html

    PR NEWSWIRE
    15 Mar 2023
    Share Share
    InDex updates the timeline of the phase III study CONCLUDE with cobitolimod
    InDex updates the timeline of the phase III study CONCLUDE with cobitolimod

    27 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/index-pharmaceuticals-updates-the-timeline-of-the-phase-iii-study-conclude-with-cobitolimod-301732412.html

    PR NEWSWIRE
    27 Jan 2023
    Share Share